Navigation Links
FDA's New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
Date:8/24/2010

WALTHAM, Mass., Aug. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing medications. Most notably, the FDA controls state that LABA/ICS combination medications should be reserved for patients who remain uncontrolled despite treatment with controller medications (e.g., single-agent ICS therapies).

According to the new report entitled Treatment Algorithms in Asthma, more than 40 percent of surveyed physicians report that they will decrease their prescribing of LABA/ICS combinations prior to attempting treatment with a single-agent ICS drug over the next 12 months.

While surveyed physicians indicate that the FDA controls for LABA-containing drugs will affect their decision to prescribe a LABA/ICS combination therapy prior to attempting treatment with a single-agent ICS, surveyed physicians also report that first-line prescribing of LABA/ICS combinations remains common. In particular, surveyed physicians are most likely to prescribe a LABA/ICS combination, such as GlaxoSmithKline's Advair or AstraZeneca's Symbicort, as a first-line maintenance therapy for newly diagnosed adult patients with moderate or severe persistent asthma.

"Some surveyed physicians say they will decrease their use of LABA/ICS combination medications for the treatment of asthma, a trend that may have positive implications for the single-agent ICS class of therapies," said Decision Resources Analyst Martin Quinn. "As a result, marketers of LABA/ICS combination medications and single-agent ICS therapies must focus not only on competitive dyna
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... WAYNE, Pa. , April 1, 2015 /PRNewswire/ ... fully integrated specialty pharmaceutical company focused on developing, ... the pricing of an offering of $60.0 million ... due 2020 (the "notes") in a private placement ... under the Securities Act of 1933, as amended ...
(Date:4/1/2015)... SAN CLEMENTE, Calif. , April 1, 2015 /PRNewswire/ ... residents in the United States ... out amongst their resident colleagues. In its inaugural year, ... and 50 of the top nominations were narrowed to ... voting process that saw over 10,000 votes from colleagues ...
(Date:4/1/2015)... CREEK, Calif. , April 1, 2015  For ... huge difference.  When this is the case, having the ... No one understands this truth better than software solutions ... laboratory management software QATrax.  Recently, the company announced the ... very enthusiastic response from clients. ...
Breaking Medicine Technology:Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 2Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 3Second Annual $25,000 Honorarium for Exceptional Medical Residents to Accept Nominations in April 2015 4TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 Baby Bellies ... providing the latest information on the top products and ... set the Guinness World Records title for "Mommy Moments” ... of the 1st annual Baby Bellies & Beyond Expo ... and the Guinness World Record will commence at 11:00am ...
(Date:4/1/2015)... Bethesda, MD, Alexandria, VA (PRWEB) April 01, 2015 ... Pathology (ASCP), the College of American Pathologists (CAP), ... American Society of Clinical Oncology (ASCO) today released ... the use of molecular marker testing for patients ... guideline will help establish standard molecular marker testing, ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might ... latest post discusses Teen Violence Related to Substance Abuse. ... Violence Awareness Month, the substance abuse treatment center has ... parents identify if there may be problems with their ... or alcohol. , “People learn how to establish healthy ...
(Date:4/1/2015)... 01, 2015 Like a mosaic slowly ... scientific understanding of the potential causes of rosacea. April ... National Rosacea Society (NRS) to educate the public on ... disorder now estimated to affect more than 16 million ... research on rosacea through its patient-funded research grants program, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Dr. ... and Distinguished Teaching Professor of the Department of Plastic ... other doctors to review reports of blindness resulting from ... surgery . The group published their study, along with ... Reconstructive Surgery journal. , "We began to see increasing ...
Breaking Medicine News(10 mins):Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 2Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 3Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 4Health News:It’s Becoming Clear: Rosacea Awareness Month Highlights Potential Causes of Rosacea 5Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
... international comparison of the care of patients with rectal ... use of chemotherapy and radiotherapy between European countries. ... by ECCO the European CanCer Organisation compared ... and The Netherlands who were diagnosed with rectal cancer ...
... options for patients with bone metastases from advanced prostate ... Phase III study of an alpha-pharmaceutical in these patients ... to research reported today (Saturday) at the 2011 European ... Chris Parker, Consultant Clinical Oncologist at the Royal Marsden ...
... , FRIDAY, Sept. 23 (HealthDay News) -- People,s bodies ... new study suggests black men who live in areas of ... have vitamin D deficiency than whites who live in the ... current vitamin D recommendations need to change. "This study shows ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) ... women be vaccinated against human papillomavirus, a sexually transmitted disease ... recommendation does not extend to boys and young men. ... over whether males also should be vaccinated for human papillomavirus, ...
... Sept. 23 (HealthDay News) -- Researchers have identified five new ... attack and coronary artery disease -- the most common cause ... a new study. The international consortium said their ... develop new treatments for the condition. In conducting the ...
... [Nairobi, 23 September 2011] East Africa is fighting the ... the region through the Leishmaniasis East Africa Platform (LEAP) ... therapy (SSG&PM) which is cheaper and nearly halves the ... injections to 17 days. East African endemic countries are ...
Cached Medicine News:Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 3Health News:Scientists ID More Genes Linked to Heart Disease 2Health News:New treatment for kala azar, the most deadly parasitic disease after malaria 2Health News:New treatment for kala azar, the most deadly parasitic disease after malaria 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: